A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: A Southwest oncology group study
Year: 1975
Type: article
Study design: Clinical Trial
Abstract: In March of 1972, the Southwest Oncology Group initiated a Phase II study, No. 7200, utilizing methyl-CCNU in the treatment of patients with solid tumors and lymphomas. Initially, they received 200 mg/m2 orally as a single dose every 6 weeks. The dose was subsequently reduced in poor-risk patients to 150 mg/m2. There were 69 responses noted in 675 evaluable patients (10%). The highest response rates were noted in patients with Hodgkin's disease (13/31, 35%), malignant gliomas of the brain (8/29, 28%), anaplastic carcinomas of the lung (5/20, 25%), and squamous cell carcinomas of the head and neck (5/29, 17%). Squamous cell tumors appeared to be more responsive than adenocarcinomas (15% vs. 5%, respectively). Hematologic toxicity was cumulative, and was influenced by dose and prior treatment. There appeared to be no cross-resistance in patients previously treated with alkylating agents. Methyl-CCNU is an active antineoplastic agent. Further studies are indicated in order to determine relative effectiveness.
Source: Cancer
Authors: Bill L. Tranum, Arthur Haut, Saul Rivkin, Edward Weber, Joseph M. Quagliana, Michael Shaw, William G. Tucker, Frank E. Smith, Michael Samson, Jeffrey Gottlieb
Institutions: University of Arkansas Medical Center, Swedish Medical Center, Tulane University, University of Nevada, Las Vegas, University of Utah, University of Utah Hospital, Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Baylor College of Medicine, Wayne State University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W1967650485